Heterogeneity of Histological Transformation Events in Waldenström's Macroglobulinemia (WM) and Related Disorders

Owen, Roger G.; Bynoe, A G; Varghese, Abraham; Tute, Ruth M. de; Rawstron, Andy C.

doi:10.3816/clml.2011.n.042

Cited by 28 publications

(27 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Transformation into DLBCL has been reported at a rate of 3% per year in patients with follicular lymphoma [22], but aggressive transformation may occur in every subtype of indolent NHL [23], including WM [24,25]. Patients who develop histologic transformation experience poor survival [22], which may have improved with the addition of rituximab to chemotherapy and highdose chemotherapy followed by autologous stem cell rescue [23].…”

Section: Discussionmentioning

confidence: 99%

Survival outcomes of secondary cancers in patients with waldenström macroglobulinemia: An analysis of the SEER database

et al. 2015

View full text Add to dashboard Cite

We hypothesized that survival outcomes of WM patients who develop SM is distinct from the general population of individuals who develop those same malignancies. Using the SEER-18 data (2000-2011), we identified patients with cancers of the breast, prostate, lung, colorectum, bladder, melanoma, non-Hodgkin lymphoma (NHL), and acute leukemia, and compared their outcomes according to having antecedent WM or not. The outcome of interest was overall survival (OS), which was analyzed in proportional-hazard models adjusted for age, sex, race, and stage. We found that patients with WM who developed SM were older than population controls with those same cancers. In the multivariate analysis, WM cases with colorectal cancer (HR 1.97; P < 0.001), melanoma (HR 2.63; P < 0.001) and NHL (HR 5 1.35; P 5 0.02) had worse OS than controls with those respective cancers. WM patients with diffuse large B-cell lymphoma also had worse OS (HR 5 1.86; P 5 0.008). The utilization of surgery and radiation was similar between WM cases and controls, except lower rates of prostatectomy and melanoma surgery among WM patients. The survival of WM patients with colorectal cancer, melanoma, and NHL is worse than among general population controls, arguing in favor of age-appropriate cancer screening.

show abstract

Section: Discussionmentioning

confidence: 99%

Survival outcomes of secondary cancers in patients with waldenström macroglobulinemia: An analysis of the SEER database

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Another area of concern from a diagnostic and clinical management point of view is the possibility that the low-grade lymphoma, WM, progresses to the high-grade lymphoma, diffuse large B cell lymphoma (DLBCL). This is usually associated with aggressive clinical course, profound cytopenias, extramedullary disease, and poor outcome [32]. The potentially diverse nature of “histological transformation events” in patients with WM, including those involving EBV (Epstein-Barr virus) infection, is increasingly recognized [32].…”

Section: Clinical Aspects Of Wm: a Brief Overviewmentioning

confidence: 99%

“…This is usually associated with aggressive clinical course, profound cytopenias, extramedullary disease, and poor outcome [32]. The potentially diverse nature of “histological transformation events” in patients with WM, including those involving EBV (Epstein-Barr virus) infection, is increasingly recognized [32]. …”

Section: Clinical Aspects Of Wm: a Brief Overviewmentioning

confidence: 99%

Waldenström Macroglobulinemia: Clinical and Immunological Aspects, Natural History, Cell of Origin, and Emerging Mouse Models

Janz

2013

ISRN Hematology

View full text Add to dashboard Cite

Waldenström macroglobulinemia (WM) is a rare and currently incurable neoplasm of IgM-expressing B-lymphocytes that is characterized by the occurrence of a monoclonal IgM (mIgM) paraprotein in blood serum and the infiltration of the hematopoietic bone marrow with malignant lymphoplasmacytic cells. The symptoms of patients with WM can be attributed to the extent and tissue sites of tumor cell infiltration and the magnitude and immunological specificity of the paraprotein. WM presents fascinating clues on neoplastic B-cell development, including the recent discovery of a specific gain-of-function mutation in the MYD88 adapter protein. This not only provides an intriguing link to new findings that natural effector IgM+IgD+ memory B-cells are dependent on MYD88 signaling, but also supports the hypothesis that WM derives from primitive, innate-like B-cells, such as marginal zone and B1 B-cells. Following a brief review of the clinical aspects and natural history of WM, this review discusses the thorny issue of WM's cell of origin in greater depth. Also included are emerging, genetically engineered mouse models of human WM that may enhance our understanding of the biologic and genetic underpinnings of the disease and facilitate the design and testing of new approaches to treat and prevent WM more effectively.

show abstract

“…[1][2][3] The disease course for WM is heterogeneous, and can range from asymptomatic (smoldering) disease to symptomatic disease presenting with profound cytopenias and end organ damage. [1][2][3] The disease course for WM is heterogeneous, and can range from asymptomatic (smoldering) disease to symptomatic disease presenting with profound cytopenias and end organ damage.…”

Section: Introductionmentioning

confidence: 99%

Impact of MYD88^L265P mutation status on histological transformation of Waldenström Macroglobulinemia

et al. 2019

View full text Add to dashboard Cite

95:274-281. wileyonlinelibrary.com/journal/ajh IgM, median (range), mg/dL 512.5 (31-6500) LDH, median (range), U/L 289 (99-3191) LDH high, n (%) 19 (53) Hemoglobin, median (range), g/dL 11.5 (3.5-15.4) Platelet count, median (range), 10 9 /L 199 (9-576) β-2 microglobulin, median (range), μg/dL 4.9 (3.3-15) Bone marrow involvement by transformed lymphoma, median % (range) 50 (5-80) Abbreviations: FLCR, free light chain ratio; GCB, germinal center B-cell; LDH, lactate dehydrogenase. ZANWAR ET AL. 277

show abstract

Heterogeneity of Histological Transformation Events in Waldenström's Macroglobulinemia (WM) and Related Disorders

Cited by 28 publications

References 22 publications

Survival outcomes of secondary cancers in patients with waldenström macroglobulinemia: An analysis of the SEER database

Survival outcomes of secondary cancers in patients with waldenström macroglobulinemia: An analysis of the SEER database

Waldenström Macroglobulinemia: Clinical and Immunological Aspects, Natural History, Cell of Origin, and Emerging Mouse Models

Impact of MYD88^L265P mutation status on histological transformation of Waldenström Macroglobulinemia

Contact Info

Product

Resources

About

Heterogeneity of Histological Transformation Events in Waldenström's Macroglobulinemia (WM) and Related Disorders

Cited by 28 publications

References 22 publications

Survival outcomes of secondary cancers in patients with waldenström macroglobulinemia: An analysis of the SEER database

Survival outcomes of secondary cancers in patients with waldenström macroglobulinemia: An analysis of the SEER database

Waldenström Macroglobulinemia: Clinical and Immunological Aspects, Natural History, Cell of Origin, and Emerging Mouse Models

Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia

Contact Info

Product

Resources

About

Impact of MYD88^L265P mutation status on histological transformation of Waldenström Macroglobulinemia